Farnesyltransferase inhibitors and myeloid malignancies: Phase I evidence of Zarnestra activity in high-risk leukemias

Jeffrey E. Lancet, Joseph D Rosenblatt, Judith E. Karp

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Acute leukemia carries a poor prognosis, especially in older patients, emphasizing the need for novel therapies. Reasons for treatment failure include high rates of relapse and treatment-related toxicities. Farnesyltransferase inhibitors (FTIs), a new class of agents that can interfere with intracellular signaling, are good therapeutic candidates for study in these diseases, given the relatively high levels of the target enzyme, farnesyltransferase, expressed in bone marrow and by peripheral circulating lymphocytes. ZARNESTRA™ (formerly R115777, Ortho Biotech Oncology, Raritan, NJ) is an FTI that has clinical activity in solid tumors and antileukemic activity in vitro. In a phase I trial of Zarnestra in patients with high-risk leukemia (resistant or relapsed acute myeloid leukemia [AML] or acute lymphocytic leukemia [ALL], chronic myeloid leukemia [CML] in blast crisis, or AML in poor prognosis subgroups), patients experienced an overall response rate of 29%. Zarnestra was well tolerated with no dose-limiting toxicities through doses up to 900 mg twice daily. Assays measuring inhibition of farnesyltransferase activity showed a reliable inhibition at doses greater than 300 mg twice daily, and pharmacokinetic studies indicated that Zarnestra accumulated preferentially in the bone marrow in a dose-dependent fashion. These results suggest that Zarnestra should be studied further in patients with myeloid leukemia.

Original languageEnglish
Pages (from-to)31-35
Number of pages5
JournalSeminars in Hematology
Volume39
Issue number3 SUPPL. 2
StatePublished - Jul 1 2002

Fingerprint

tipifarnib
Farnesyltranstransferase
Leukemia
Neoplasms
Acute Myeloid Leukemia
Bone Marrow
Blast Crisis
Myeloid Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Treatment Failure
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Therapeutics
Pharmacokinetics
Lymphocytes
Recurrence
Enzymes

ASJC Scopus subject areas

  • Hematology

Cite this

Farnesyltransferase inhibitors and myeloid malignancies : Phase I evidence of Zarnestra activity in high-risk leukemias. / Lancet, Jeffrey E.; Rosenblatt, Joseph D; Karp, Judith E.

In: Seminars in Hematology, Vol. 39, No. 3 SUPPL. 2, 01.07.2002, p. 31-35.

Research output: Contribution to journalArticle

@article{530e91d0c8334789b79be41bc6f104cf,
title = "Farnesyltransferase inhibitors and myeloid malignancies: Phase I evidence of Zarnestra activity in high-risk leukemias",
abstract = "Acute leukemia carries a poor prognosis, especially in older patients, emphasizing the need for novel therapies. Reasons for treatment failure include high rates of relapse and treatment-related toxicities. Farnesyltransferase inhibitors (FTIs), a new class of agents that can interfere with intracellular signaling, are good therapeutic candidates for study in these diseases, given the relatively high levels of the target enzyme, farnesyltransferase, expressed in bone marrow and by peripheral circulating lymphocytes. ZARNESTRA™ (formerly R115777, Ortho Biotech Oncology, Raritan, NJ) is an FTI that has clinical activity in solid tumors and antileukemic activity in vitro. In a phase I trial of Zarnestra in patients with high-risk leukemia (resistant or relapsed acute myeloid leukemia [AML] or acute lymphocytic leukemia [ALL], chronic myeloid leukemia [CML] in blast crisis, or AML in poor prognosis subgroups), patients experienced an overall response rate of 29{\%}. Zarnestra was well tolerated with no dose-limiting toxicities through doses up to 900 mg twice daily. Assays measuring inhibition of farnesyltransferase activity showed a reliable inhibition at doses greater than 300 mg twice daily, and pharmacokinetic studies indicated that Zarnestra accumulated preferentially in the bone marrow in a dose-dependent fashion. These results suggest that Zarnestra should be studied further in patients with myeloid leukemia.",
author = "Lancet, {Jeffrey E.} and Rosenblatt, {Joseph D} and Karp, {Judith E.}",
year = "2002",
month = "7",
day = "1",
language = "English",
volume = "39",
pages = "31--35",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "3 SUPPL. 2",

}

TY - JOUR

T1 - Farnesyltransferase inhibitors and myeloid malignancies

T2 - Phase I evidence of Zarnestra activity in high-risk leukemias

AU - Lancet, Jeffrey E.

AU - Rosenblatt, Joseph D

AU - Karp, Judith E.

PY - 2002/7/1

Y1 - 2002/7/1

N2 - Acute leukemia carries a poor prognosis, especially in older patients, emphasizing the need for novel therapies. Reasons for treatment failure include high rates of relapse and treatment-related toxicities. Farnesyltransferase inhibitors (FTIs), a new class of agents that can interfere with intracellular signaling, are good therapeutic candidates for study in these diseases, given the relatively high levels of the target enzyme, farnesyltransferase, expressed in bone marrow and by peripheral circulating lymphocytes. ZARNESTRA™ (formerly R115777, Ortho Biotech Oncology, Raritan, NJ) is an FTI that has clinical activity in solid tumors and antileukemic activity in vitro. In a phase I trial of Zarnestra in patients with high-risk leukemia (resistant or relapsed acute myeloid leukemia [AML] or acute lymphocytic leukemia [ALL], chronic myeloid leukemia [CML] in blast crisis, or AML in poor prognosis subgroups), patients experienced an overall response rate of 29%. Zarnestra was well tolerated with no dose-limiting toxicities through doses up to 900 mg twice daily. Assays measuring inhibition of farnesyltransferase activity showed a reliable inhibition at doses greater than 300 mg twice daily, and pharmacokinetic studies indicated that Zarnestra accumulated preferentially in the bone marrow in a dose-dependent fashion. These results suggest that Zarnestra should be studied further in patients with myeloid leukemia.

AB - Acute leukemia carries a poor prognosis, especially in older patients, emphasizing the need for novel therapies. Reasons for treatment failure include high rates of relapse and treatment-related toxicities. Farnesyltransferase inhibitors (FTIs), a new class of agents that can interfere with intracellular signaling, are good therapeutic candidates for study in these diseases, given the relatively high levels of the target enzyme, farnesyltransferase, expressed in bone marrow and by peripheral circulating lymphocytes. ZARNESTRA™ (formerly R115777, Ortho Biotech Oncology, Raritan, NJ) is an FTI that has clinical activity in solid tumors and antileukemic activity in vitro. In a phase I trial of Zarnestra in patients with high-risk leukemia (resistant or relapsed acute myeloid leukemia [AML] or acute lymphocytic leukemia [ALL], chronic myeloid leukemia [CML] in blast crisis, or AML in poor prognosis subgroups), patients experienced an overall response rate of 29%. Zarnestra was well tolerated with no dose-limiting toxicities through doses up to 900 mg twice daily. Assays measuring inhibition of farnesyltransferase activity showed a reliable inhibition at doses greater than 300 mg twice daily, and pharmacokinetic studies indicated that Zarnestra accumulated preferentially in the bone marrow in a dose-dependent fashion. These results suggest that Zarnestra should be studied further in patients with myeloid leukemia.

UR - http://www.scopus.com/inward/record.url?scp=0036656207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036656207&partnerID=8YFLogxK

M3 - Article

C2 - 12214291

AN - SCOPUS:0036656207

VL - 39

SP - 31

EP - 35

JO - Seminars in Hematology

JF - Seminars in Hematology

SN - 0037-1963

IS - 3 SUPPL. 2

ER -